Skip Nav Destination
Issues
1 March 2019
-
Cover Image
Cover Image
Carrer and colleagues observed that the enzyme ATP-citrate lyase (ACLY) increases production of acetyl-CoA and promotes acinar-ductal metaplasia (ADM) and tumorigenesis in Kras-mutant pancreatic cells through increased acetyl-coA availability for histone acetylation and the mevalonate pathway. This in turn renders PDAC sensitive to inhibitors of the BET family of proteins, which recognize acetylated histones, and statins, which target the mevalonate pathway. These findings suggest that acetyl-coA plays key metabolic and signaling roles in PDAC and that targeting acetyl-coA–dependent processes may be a potential therapeutic strategy. For details, please see the article by Carrer and colleagues on page 416. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Review
Research Brief
Author Choice
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery; Mary Ann Anderson; Jia-nan Gong; Rachel Thijssen; Richard W. Birkinshaw; Ella R. Thompson; Charis E. Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E. Lew; Ian J. Majewski; Daniel H.D. Gray; David A. Westerman; Constantine S. Tam; John F. Seymour; Peter E. Czabotar; David C.S. Huang; Andrew W. Roberts
Research Articles
Author Choice
A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Sheau W. Lok; James R. Whittle; François Vaillant; Charis E. Teh; Louisa L. Lo; Antonia N. Policheni; Alice R.T. Bergin; Jayesh Desai; Sarah Ftouni; Luke C. Gandolfo; Danny Liew; He K. Liu; G. Bruce Mann; Kate Moodie; Anand Murugasu; Bhupinder Pal; Andrew W. Roberts; Mark A. Rosenthal; Kylie Shackleton; Maria João Silva; Zhen R. Siow; Gordon K. Smyth; Leanne Taylor; Avraham Travers; Belinda Yeo; Miriam M. Yeung; Andjelija Zivanovic Bujak; Sarah-Jane Dawson; Daniel H.D. Gray; Jane E. Visvader; Geoffrey J. Lindeman
Author Choice
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver; Guillermo Garcia-Manero; Sreyashi Basu; Prajwal C. Boddu; Mansour Alfayez; Jorge E. Cortes; Marina Konopleva; Farhad Ravandi-Kashani; Elias Jabbour; Tapan Kadia; Graciela M. Nogueras-Gonzalez; Jing Ning; Naveen Pemmaraju; Courtney D. DiNardo; Michael Andreeff; Sherry A. Pierce; Tauna Gordon; Steven M. Kornblau; Wilmer Flores; Zainab Alhamal; Carlos Bueso-Ramos; Jeffrey L. Jorgensen; Keyur P. Patel; Jorge Blando; James P. Allison; Padmanee Sharma; Hagop Kantarjian
Author Choice
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Alexander Drilon; Siqing Fu; Manish R. Patel; Marwan Fakih; Ding Wang; Anthony J. Olszanski; Daniel Morgensztern; Stephen V. Liu; Byoung Chul Cho; Lyudmila Bazhenova; Cristina P. Rodriguez; Robert C. Doebele; Antoinette Wozniak; Karen L. Reckamp; Tara Seery; Petros Nikolinakos; Zheyi Hu; Jennifer W. Oliver; Denise Trone; Katherine McArthur; Rupal Patel; Pratik S. Multani; Myung-Ju Ahn
Author Choice
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma
Rani Ojha; Nektaria M. Leli; Angelique Onorati; Shengfu Piao; Ioannis I. Verginadis; Feven Tameire; Vito W. Rebecca; Cynthia I. Chude; Sengottuvelan Murugan; Colin Fennelly; Estela Noguera-Ortega; Charleen T. Chu; Shujing Liu; Xiaowei Xu; Clemens Krepler; Min Xiao; Wei Xu; Zhi Wei; Dennie T. Frederick; Genevieve Boland; Tara C. Mitchell; Giorgos C. Karakousis; Lynn M. Schuchter; Keith T. Flaherty; Gao Zhang; Meenhard Herlyn; Constantinos Koumenis; Ravi K. Amaravadi
Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis
Alessandro Carrer; Sophie Trefely; Steven Zhao; Sydney L. Campbell; Robert J. Norgard; Kollin C. Schultz; Simone Sidoli; Joshua L.D. Parris; Hayley C. Affronti; Sharanya Sivanand; Shaun Egolf; Yogev Sela; Marco Trizzino; Alessandro Gardini; Benjamin A. Garcia; Nathaniel W. Snyder; Ben Z. Stanger; Kathryn E. Wellen
Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL
Agnieszka A. Wendorff; S. Aidan Quinn; Marissa Rashkovan; Chioma J. Madubata; Alberto Ambesi-Impiombato; Mark R. Litzow; Martin S. Tallman; Elisabeth Paietta; Maddalena Paganin; Giuseppe Basso; Julie M. Gastier-Foster; Mignon L. Loh; Raul Rabadan; Pieter Van Vlierberghe; Adolfo A. Ferrando
News in Brief
Research Watch
Autophagy
Clinical Trials
Drug Design
Epigenetics
Gliomas
Immunology
Leukemia
Metabolism
Metastasis
Oncogenes
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.